The decision came right after the US regulator also cleared Bristol-Myers Squibb and 2seventy bio’s rival CAR-T Abecma as a third-line therapy for relapsed or refractory multiple myeloma, moving the cell therapies much earlier in the treatment pathway from their current fifth-line use.
Carvykti (ciltacabtagene autoleucel) can now be used after first relapse in patients who have been previously treated with a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and are refractory to lenalidomide.
